$BNGO
Bionano Genomics, Inc.

2021 Q4 Form 10-Q Financial Statement

#000141169021000030 Filed on November 04, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q4
Revenue $6.302M $4.655M $3.990M
YoY Change 57.94% 111.98% 43.06%
Cost Of Revenue $6.063M $3.501M $2.810M
YoY Change 115.77% 139.79% 66.2%
Gross Profit $239.0K $1.154M $1.180M
YoY Change -79.75% 56.79% 7.43%
Gross Profit Margin 3.79% 24.79% 29.57%
Selling, General & Admin $18.31M $15.33M $9.030M
YoY Change 102.74% 77.01% 54.1%
% of Gross Profit 7659.83% 1328.16% 765.25%
Research & Development $9.215M $6.505M $2.880M
YoY Change 219.97% 182.34% 20.0%
% of Gross Profit 3855.65% 563.69% 244.07%
Depreciation & Amortization $1.880M $526.0K $570.0K
YoY Change 229.82% 64.38% 78.13%
% of Gross Profit 786.61% 45.58% 48.31%
Operating Expenses $27.52M $21.83M $11.91M
YoY Change 131.08% 99.14% 44.19%
Operating Profit -$27.28M -$20.68M -$10.73M
YoY Change 154.27% 102.19% 49.83%
Interest Expense $30.00K $27.00K -$610.0K
YoY Change -104.92% -95.42% -29.89%
% of Operating Profit
Other Income/Expense, Net $37.00K -$40.00K -$10.00K
YoY Change -470.0% -92.52% -101.82%
Pretax Income -$28.72M -$20.72M -$11.74M
YoY Change 144.6% 92.51% 48.8%
Income Tax -$5.767M $35.00K -$10.00K
% Of Pretax Income
Net Earnings -$22.95M -$20.75M -$11.73M
YoY Change 95.64% 92.3% 48.48%
Net Earnings / Revenue -364.15% -445.82% -293.98%
Basic Earnings Per Share -$0.07
Diluted Earnings Per Share -$80.82K -$0.07 -$74.66K
COMMON SHARES
Basic Shares Outstanding 289.2M shares 280.2M shares 153.2M shares
Diluted Shares Outstanding 280.2M shares

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $250.6M $326.0M $38.45M
YoY Change 551.8% 1624.87% 122.25%
Cash & Equivalents $24.57M $140.7M $38.45M
Short-Term Investments $226.0M $185.3M $0.00
Other Short-Term Assets $2.348M $3.962M $462.0K
YoY Change 408.23% 108.53% 1.08%
Inventory $12.39M $9.020M $3.315M
Prepaid Expenses
Receivables $4.934M $2.996M $2.775M
Other Receivables $387.0K $0.00 $0.00
Total Short-Term Assets $272.4M $342.0M $46.79M
YoY Change 482.22% 1069.79% 65.58%
LONG-TERM ASSETS
Property, Plant & Equipment $10.32M $8.554M $4.910M
YoY Change 110.14% 135.32% 151.84%
Goodwill $56.16M $7.173M $7.173M
YoY Change 682.94% 3.34%
Intangibles $26.84M $1.238M $1.475M
YoY Change 1719.8% -21.65%
Long-Term Investments
YoY Change
Other Assets $749.0K $645.0K $103.0K
YoY Change 627.18%
Total Long-Term Assets $104.7M $17.61M $13.66M
YoY Change 666.31% 44.87% 600.7%
TOTAL ASSETS
Total Short-Term Assets $272.4M $342.0M $46.79M
Total Long-Term Assets $104.7M $17.61M $13.66M
Total Assets $377.1M $359.7M $60.45M
YoY Change 523.82% 768.82% 100.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.696M $7.875M $2.930M
YoY Change 230.92% 39.01% 8.55%
Accrued Expenses $9.694M $9.416M $5.599M
YoY Change 73.14% 110.84% 73.59%
Deferred Revenue $684.0K $411.0K $416.0K
YoY Change 64.42% -0.24% 16.2%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $299.0K $0.00
YoY Change -100.0%
Total Short-Term Liabilities $21.84M $17.70M $8.945M
YoY Change 144.16% -28.57% -66.08%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $16.33M
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $14.50M $232.0K $0.00
YoY Change 209.33% -100.0%
Total Long-Term Liabilities $0.00 $232.0K $16.33M
YoY Change -100.0% -87.46% 36602.71%
TOTAL LIABILITIES
Total Short-Term Liabilities $21.84M $17.70M $8.945M
Total Long-Term Liabilities $0.00 $232.0K $16.33M
Total Liabilities $39.98M $18.09M $25.37M
YoY Change 57.61% -32.29% -4.61%
SHAREHOLDERS EQUITY
Retained Earnings -$216.1M -$193.2M -$143.7M
YoY Change 50.41% 46.34% 40.04%
Common Stock $553.8M $534.9M $178.8M
YoY Change 209.78% 264.76% 68.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $337.1M $341.6M $35.08M
YoY Change
Total Liabilities & Shareholders Equity $377.1M $359.7M $60.45M
YoY Change 523.82% 768.82% 100.11%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q4
OPERATING ACTIVITIES
Net Income -$22.95M -$20.75M -$11.73M
YoY Change 95.64% 92.3% 48.48%
Depreciation, Depletion And Amortization $1.880M $526.0K $570.0K
YoY Change 229.82% 64.38% 78.13%
Cash From Operating Activities -$25.62M -$19.98M -$12.10M
YoY Change 111.75% 82.32% 27.64%
INVESTING ACTIVITIES
Capital Expenditures -$478.0K -$268.0K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$92.03M -$185.3M $0.00
YoY Change 7464.65%
Cash From Investing Activities -$92.51M -$185.6M $0.00
YoY Change 7475.59% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.967M 13.77M 31.68M
YoY Change -93.79% -8.77% 70.41%
NET CHANGE
Cash From Operating Activities -25.62M -19.98M -12.10M
Cash From Investing Activities -92.51M -185.6M 0.000
Cash From Financing Activities 1.967M 13.77M 31.68M
Net Change In Cash -116.2M -191.8M 19.58M
YoY Change -693.28% -11517.74% 115.4%
FREE CASH FLOW
Cash From Operating Activities -$25.62M -$19.98M -$12.10M
Capital Expenditures -$478.0K -$268.0K $0.00
Free Cash Flow -$25.14M -$19.71M -$12.10M
YoY Change 107.8% 79.87% 27.91%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001411690
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P3M
CY2021Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2021Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Address Address Line1
EntityAddressAddressLine1
9540 Towne Centre Drive, Suite 100
dei Local Phone Number
LocalPhoneNumber
888-7600
dei Entity File Number
EntityFileNumber
001-38613
dei Entity Registrant Name
EntityRegistrantName
Bionano Genomics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-1756290
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
858
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
289184109 shares
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
140736000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38449000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
185333000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0 USD
CY2021Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2015000 USD
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2119000 USD
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2996000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2775000 USD
CY2021Q3 us-gaap Inventory Net
InventoryNet
9020000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
3316000 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3962000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2250000 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
342047000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
46790000 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8554000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4910000 USD
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1238000 USD
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1475000 USD
CY2021Q3 us-gaap Goodwill
Goodwill
7173000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
7173000 USD
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
645000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
103000 USD
CY2021Q3 us-gaap Assets
Assets
359657000 USD
CY2020Q4 us-gaap Assets
Assets
60451000 USD
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
7875000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2930000 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9416000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5599000 USD
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
411000 USD
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
416000 USD
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
17702000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8945000 USD
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0 USD
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
16326000 USD
CY2021Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
158000 USD
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
98000 USD
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
232000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 USD
CY2021Q3 us-gaap Liabilities
Liabilities
18092000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
25369000 USD
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
281441000 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
281441000 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
189953000 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
189953000 shares
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
28000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
19000 USD
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
534823000 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
178747000 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-193170000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-143684000 USD
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-116000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
341565000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
35082000 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
359657000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
60451000 USD
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4655000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2196000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11679000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4513000 USD
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3501000 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1460000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
8044000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2919000 USD
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6505000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2304000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13270000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7379000 USD
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
15327000 USD
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8659000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
38683000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
21640000 USD
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
21832000 USD
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
10963000 USD
us-gaap Costs And Expenses
CostsAndExpenses
51953000 USD
us-gaap Costs And Expenses
CostsAndExpenses
29019000 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-20678000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10227000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-48318000 USD
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-40000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-27425000 USD
CY2021Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
27000 USD
CY2020Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-589000 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-721000 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1911000 USD
CY2021Q3 bngo Gain Loss On Forgiveness Of Paycheck Protection Program Loan
GainLossOnForgivenessOfPaycheckProtectionProgramLoan
0 USD
CY2020Q3 bngo Gain Loss On Forgiveness Of Paycheck Protection Program Loan
GainLossOnForgivenessOfPaycheckProtectionProgramLoan
0 USD
bngo Gain Loss On Forgiveness Of Paycheck Protection Program Loan
GainLossOnForgivenessOfPaycheckProtectionProgramLoan
1775000 USD
bngo Gain Loss On Forgiveness Of Paycheck Protection Program Loan
GainLossOnForgivenessOfPaycheckProtectionProgramLoan
0 USD
CY2021Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2020Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2076000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-67000 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
54000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-96000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-535000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1118000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1911000 USD
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-20718000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10762000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-49436000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29336000 USD
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
35000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
30000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
50000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
40000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-20753000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-10792000 USD
us-gaap Net Income Loss
NetIncomeLoss
-49486000 USD
us-gaap Net Income Loss
NetIncomeLoss
-29376000 USD
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
280173000 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
280173000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
132942000 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
132942000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
274392000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
274392000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86632000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
86632000 shares
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-20753000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-10792000 USD
us-gaap Net Income Loss
NetIncomeLoss
-49486000 USD
us-gaap Net Income Loss
NetIncomeLoss
-29376000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-116000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-116000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 USD
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20869000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10792000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-49602000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29376000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
3614000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
328000 USD
CY2020Q1 bngo Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
2355000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-10510000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-4213000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
328000 USD
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
16366000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
21000 USD
CY2020Q2 bngo Stock Issued During Period Value Covenant Waiver
StockIssuedDuringPeriodValueCovenantWaiver
300000 USD
CY2020Q2 bngo Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
1109000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-8074000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
5837000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
447000 USD
CY2020Q3 bngo Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
15083000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
4101000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-10792000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
14676000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
35082000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
333000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
371000 USD
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
327486000 USD
CY2021Q1 bngo Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
9393000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-9947000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
362718000 USD
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
89000 USD
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
242000 USD
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2788000 USD
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13537000 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1758000 USD
CY2021Q2 bngo Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
22000 USD
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
65000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-18786000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
345866000 USD
CY2021Q3 bngo Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
1000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-20753000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-116000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
341565000 USD
us-gaap Net Income Loss
NetIncomeLoss
-49486000 USD
us-gaap Net Income Loss
NetIncomeLoss
-29376000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1490000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
909000 USD
us-gaap Paid In Kind Interest
PaidInKindInterest
178000 USD
us-gaap Paid In Kind Interest
PaidInKindInterest
952000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
4917000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1103000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1334000 USD
bngo Gain Loss On Forgiveness Of Paycheck Protection Program Loan
GainLossOnForgivenessOfPaycheckProtectionProgramLoan
1775000 USD
bngo Gain Loss On Forgiveness Of Paycheck Protection Program Loan
GainLossOnForgivenessOfPaycheckProtectionProgramLoan
0 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2076000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
336000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1709000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
10346000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3612000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2072000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
566000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4945000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
925000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
4104000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
412000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46305000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26210000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
2450000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
344000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
205334000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
0 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
20000000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
126000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-185552000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2450000 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
17010000 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
5000000 USD
bngo Proceeds From Payroll Protection Program Loan
ProceedsFromPayrollProtectionProgramLoan
0 USD
bngo Proceeds From Payroll Protection Program Loan
ProceedsFromPayrollProtectionProgramLoan
1775000 USD
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
0 USD
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
761000 USD
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
0 USD
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
2258000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
342712000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
17963000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1704000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1597000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
65000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
21000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10081000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
18551000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
334144000 USD
bngo Transfer Of Instruments And Servers From Property And Equipment Into Inventory
TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory
544000 USD
bngo Transfer Of Instruments And Servers From Property And Equipment Into Inventory
TransferOfInstrumentsAndServersFromPropertyAndEquipmentIntoInventory
134000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30216000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
102287000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1556000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38449000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17311000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
140736000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18867000 USD
us-gaap Interest Paid Net
InterestPaidNet
490000 USD
us-gaap Interest Paid Net
InterestPaidNet
991000 USD
us-gaap Stock Issued1
StockIssued1
0 USD
us-gaap Stock Issued1
StockIssued1
4100000 USD
bngo Transfer Of Instruments And Servers To Property And Equipment From Inventory
TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory
5074000 USD
bngo Transfer Of Instruments And Servers To Property And Equipment From Inventory
TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory
2618000 USD
bngo Gain Loss On Forgiveness Of Paycheck Protection Program Loan
GainLossOnForgivenessOfPaycheckProtectionProgramLoan
1775000 USD
bngo Gain Loss On Forgiveness Of Paycheck Protection Program Loan
GainLossOnForgivenessOfPaycheckProtectionProgramLoan
0 USD
bngo Stock Issued For Services
StockIssuedForServices
15000 USD
bngo Stock Issued For Services
StockIssuedForServices
0 USD
bngo Issue Common Stock For Covenant Waiver
IssueCommonStockForCovenantWaiver
116000 USD
bngo Issue Common Stock For Covenant Waiver
IssueCommonStockForCovenantWaiver
300000 USD
bngo Warrant Exercise Non Cash
WarrantExerciseNonCash
129000 USD
bngo Warrant Exercise Non Cash
WarrantExerciseNonCash
0 USD
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
140700000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
185300000 USD
CY2021Q3 bngo Working Capital
WorkingCapital
324300000 USD
CY2021Q1 bngo Gain Loss On Forgiveness Of Paycheck Protection Program Loan
GainLossOnForgivenessOfPaycheckProtectionProgramLoan
1800000 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
17000000 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15842000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
35040000 shares
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4655000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2196000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11679000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4513000 USD
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4655000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2196000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11679000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4513000 USD
CY2021Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
569000 USD
CY2021Q3 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.307
CY2021Q3 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.499
CY2021Q3 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.195
CY2021Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
79000 USD
CY2020Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
66000 USD
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
326000 USD
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
299000 USD
CY2021Q3 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
5011000 USD
CY2020Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
4894000 USD
CY2021Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2015000 USD
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2119000 USD
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2996000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2775000 USD
CY2021Q3 us-gaap Allowance For Doubtful Accounts Receivable Recoveries
AllowanceForDoubtfulAccountsReceivableRecoveries
10000 USD
us-gaap Allowance For Doubtful Accounts Receivable Recoveries
AllowanceForDoubtfulAccountsReceivableRecoveries
50000 USD
CY2021Q3 us-gaap Inventory Raw Materials And Supplies Net Of Reserves
InventoryRawMaterialsAndSuppliesNetOfReserves
1024000 USD
CY2020Q4 us-gaap Inventory Raw Materials And Supplies Net Of Reserves
InventoryRawMaterialsAndSuppliesNetOfReserves
2283000 USD
CY2021Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
7996000 USD
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1033000 USD
CY2021Q3 us-gaap Inventory Net
InventoryNet
9020000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
3316000 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
17000000 USD
CY2020Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
17756000 USD
CY2020Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1430000 USD
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
16326000 USD
CY2021Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
33368851 shares
CY2021Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
3.05
CY2021Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
101800000 USD
CY2021Q1 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
293000 USD
CY2021Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
38333352 shares
CY2021Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
6.00
CY2021Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
230000000 USD
CY2021Q1 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
435000 USD
CY2020Q3 bngo Sale Of Stock Authorized Amount To Be Issued
SaleOfStockAuthorizedAmountToBeIssued
125000000 USD
CY2020Q4 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
27025384 shares
CY2020Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.82
CY2020Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
22100000 USD
CY2020Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
573000 USD
CY2021Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
6298152 shares
CY2021Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
2.68
CY2021Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
16900000 USD
CY2021Q1 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
422000 USD
CY2021Q3 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
2256000 shares
CY2021Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
6.15
CY2021Q3 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
13900000 USD
CY2021Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
600000 USD
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
15174000 shares
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.34
CY2020 bngo Class Of Warrant Or Right Weighted Average Remaining Contractual Term Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights
P3Y9M3D
CY2020Q4 bngo Class Of Warrant Or Right Aggregate Intrinsic Value Of Warrants Or Rights
ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights
26841000 USD
bngo Class Of Warrant Or Right Number Of Securities Granted In Period
ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod
0 shares
bngo Class Of Warrant Or Right Number Of Securities Exercised In Period
ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod
10789000 shares
bngo Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercised In Period
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod
0.89
bngo Class Of Warrant Or Right Aggregate Intrinsic Value Exercised In Period Of Warrants Or Rights
ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights
58175000 USD
bngo Class Of Warrant Or Right Number Of Securities Canceled In Period
ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod
24000 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5290000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
6544000 shares
bngo Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Cancelled In Period
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelledInPeriod
3.29
CY2021Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4361000 shares
CY2021Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
5.95
bngo Class Of Warrant Or Right Weighted Average Remaining Contractual Term Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights
P2Y7D
CY2021Q3 bngo Class Of Warrant Or Right Aggregate Intrinsic Value Of Warrants Or Rights
ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights
1651000 USD
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.91
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M12D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
10178000 USD
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.11
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
371000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.49
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2187000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
802000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.35
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10661000 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.94
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
17822000 USD
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
3035000 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
3.31
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P8Y1M9D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
9326000 USD
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.64
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.35
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.78
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.43
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2788000 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
447000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4917000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1103000 USD
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.009
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.004
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.011
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.008
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.714
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.779
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.783
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.748
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2021Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
44 security
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
13000 USD

Files In Submission

Name View Source Status
0001411690-21-000030-index-headers.html Edgar Link pending
0001411690-21-000030-index.html Edgar Link pending
0001411690-21-000030.txt Edgar Link pending
0001411690-21-000030-xbrl.zip Edgar Link pending
bionano-nonxemployeedirect.htm Edgar Link pending
bngo-20210930.htm Edgar Link pending
bngo-20210930.xsd Edgar Link pending
bngo-20210930xexx311.htm Edgar Link pending
bngo-20210930xexx312.htm Edgar Link pending
bngo-20210930xexx321.htm Edgar Link pending
bngo-20210930_cal.xml Edgar Link unprocessable
bngo-20210930_def.xml Edgar Link unprocessable
bngo-20210930_htm.xml Edgar Link completed
bngo-20210930_lab.xml Edgar Link unprocessable
bngo-20210930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending